3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
2
Active not recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Conditions
Neuroendocrine Tumors
2
Thymus Neoplasms
1
Interventions
Carboplatin
98
Cisplatin
95
pembrolizumab
90
Gemcitabine
81
Paclitaxel
80
Docetaxel
73
Capecitabine
64
Oxaliplatin
53
Specimen Handling
51
Fluorouracil
51
Magnetic Resonance Spectroscopy
49
Radiotherapy
48
Bevacizumab
48
Dexamethasone
45
Cyclophosphamide
44
Leucovorin
38
Drug Therapy
38
Irinotecan
36
Doxorubicin
36
Pemetrexed
35
Injections
30
Trastuzumab
28
Vincristine
27
Rituximab
27
Radiosurgery
25
Prednisone
25
Etoposide
25
130-nm albumin-bound paclitaxel
25
Radiation
24
Lenalidomide
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Recruiting
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled
NCT05387603
2025-09-10
START-NET
Lund University Hospital
Phase 3
Recruiting
300 enrolled